Table 2.
Recent and expected approvals of second as well as third and further line therapy strategies in locally advanced and metastatic settings.
| Third and Further Lines | Second Line | ||||||
|---|---|---|---|---|---|---|---|
| Treatment | Trial Name | Tumor Type | Approval | Treatment | Trial Name | Tumor Type | Approval |
| Nivolumab | ATTRACTION-II | Gastric or GEJ adenocarcinoma | 2018: Japan, Taiwan, South Korea | Ramucirumab | REGARD | Gastric or GEJ adenocarcinoma | 2014: United States, Europe |
| Pembrolizumab | KEYNOTE-059 | Gastric or GEJ adenocarcinoma, CPS ≥ 1 | 2017: United States | Ramucirumab + Paclitaxel | RAINBOW | Gastric or GEJ adenocarcinoma | 2014: United States, Europe |
| Apatinib | ANGEL | Gastric or GEJ adenocarcinoma | 2014: China | Nab-Paclitaxel | ABSOLUTE | Gastric or GEJ adenocarcinoma | 2013: Japan |
| Trifluridine and Tipiracil | TAGS | Gastric or GEJ adenocarcinoma | 2019: United States, Europe | Pembrolizumab | KEYNOTE-181 | Oesophageal SCC + adenocarcinoma, CPS ≥ 10 | 2019: United States |
| Nivolumab | ATTRACTION-III | Oesophageal SCC | Not yet approved | ||||
| Pembrolizumab | 5 KEYNOTE studies | MSI-H (tissue agnostic approval) | 2017: United States | ||||